Jharna Medhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jharna Medhi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chandrashekar Thalluri
Faculty of Pharmaceutical Science, Assam down town University (AdtU), Guwahati, India
2 shared publications - Sarad Pawar Naik Bukke
Victoria University
2 shared publications Ananda Kumar Chettupalli
Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas Knowledge city Adamas University Kolkata West Bengal India
1 shared publication- Ananda Kumar Chettupalli
Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas Knowledge City, Adamas University
1 shared publication - Bukke Pasunath Naik
Department of Electronics and Communication Engineering (ECE), Indian Institute of Information Technology Design and Manufacturing (IIITDM) Kancheepuram
1 shared publication - Gali Avinash Kumar
Department of Pharmacognosy, Vel Pharmacy College VISTAS, Thiruvallur Pallavaram Tamil Nadu India
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in Precision Medical Sciences
Genomics and epigenomics of tissue repair: Implications for personalized medicine
The healing of tissues is a highly coordinated development process which includes cell proliferation and differentiation, immune modulation, and extracellular‐matrix remodeling. Genetic variation, which encompasses single‐nucleotide polymorphisms (SNPs) and copy‐number variations (CNVs), and epigenetic corrections such as DNA methylation, post‐translational changes to histones, and non‐coding RNA activity might impact regenerative capacity and individual response to injury. High‐throughput sequencing and molecular profiling technologies have made it feasible to conduct genome and epigenome‐wide studies, clarifying how genomic and epigenomic contributions impact reparative processes. For example, certain SNPs may alter signaling pathways that induce tissue growth and, likewise, epigenetic changes may alter gene‐expression patterns following injury that may affect healing. Furthermore, combining genomic and epigenomic data will allow for the development of therapies specific to an individual's capacity for repair and susceptibility for scarring. While biomarker discovery, the identification of molecular features that correlate with the efficiency of healing and/or responsiveness to treatment, would additionally provide a tangible example of precision regenerative medicine. Regenerative strategies targeting a genetic mutation or secondarily changing the epigenome to promote tissue healing would provide an opportunity to improve healing outcomes by connecting molecular mechanisms to therapeutic interventions, which would enhance regeneration while also minimizing fibrosis and other unwanted effects.
- 18 August 2026
- Published by Wiley in Precision Medical Sciences
Open AccessGenomics and epigenomics of tissue repair: Implications for personalized medicine
The healing of tissues is a highly coordinated development process which includes cell proliferation and differentiation, immune modulation, and extracellular‐matrix remodeling. Genetic variation, which encompasses single‐nucleotide polymorphisms (SNPs) and copy‐number variations (CNVs), and epigenetic corrections such as DNA methylation, post‐translational changes to histones, and non‐coding RNA activity might impact regenerative capacity and individual response to injury. High‐throughput sequencing and molecular profiling technologies have made it feasible to conduct genome and epigenome‐wide studies, clarifying how genomic and epigenomic contributions impact reparative processes. For example, certain SNPs may alter signaling pathways that induce tissue growth and, likewise, epigenetic changes may alter gene‐expression patterns following injury that may affect healing. Furthermore, combining genomic and epigenomic data will allow for the development of therapies specific to an individual's capacity for repair and susceptibility for scarring. While biomarker discovery, the identification of molecular features that correlate with the efficiency of healing and/or responsiveness to treatment, would additionally provide a tangible example of precision regenerative medicine. Regenerative strategies targeting a genetic mutation or secondarily changing the epigenome to promote tissue healing would provide an opportunity to improve healing outcomes by connecting molecular mechanisms to therapeutic interventions, which would enhance regeneration while also minimizing fibrosis and other unwanted effects.
- 9 June 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-34
Advanced drug delivery systems for regenerative medicine: nanobiomaterial innovations, hybrid platforms, and translational perspectives
Regenerative therapies focus on repairing, reproducing, or regenerating tissues and organs that have been harmed due to injury or illness through cellular based therapy and bioactive molecule driven systems. The advancement of this type of therapy has become increasingly dependent on progressive developments in drug delivery systems that provide controlled and sustained delivery of therapeutic agents and modulated the cellular behaviors in the target site. Nanocarriers (liposomes, extracellular vesicles, etc.) increase the biocompatibility of the drug delivery system and aid in the targeted delivery of growth factors and genetic materials. Additionally, advanced biomaterials (hydrogels, bioresorbable polymers) serve as drug delivery vehicle for the regeneration of the tissues while acting as structural scaffold to create a regenerative microenvironment. New technologies (3D cell printing, micro-fluidic systems) provide excellent ability to precisely control the spatial deployment of therapeutic agents thereby enhancing local tissue regeneration and angiogenesis. While many of these modalities have demonstrated success in preclinical studies, there are still many challenges constraining the large-scale manufacture, standardization and regulatory approval for translation into the clinic. Therefore, there is a critical need for multidisciplinary collaborative efforts to further develop scalable and effective personalized regenerative therapies to treat patients with regenerative medicine. This review proposes a hierarchical framework integrating nano-scale carriers, biomaterial platforms, and therapeutic applications, offering a unified perspective that bridges material innovation with clinical translation in regenerative medicine.
- 9 June 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- p. 1-34
Advanced drug delivery systems for regenerative medicine: nanobiomaterial innovations, hybrid platforms, and translational perspectives
Regenerative therapies focus on repairing, reproducing, or regenerating tissues and organs that have been harmed due to injury or illness through cellular based therapy and bioactive molecule driven systems. The advancement of this type of therapy has become increasingly dependent on progressive developments in drug delivery systems that provide controlled and sustained delivery of therapeutic agents and modulated the cellular behaviors in the target site. Nanocarriers (liposomes, extracellular vesicles, etc.) increase the biocompatibility of the drug delivery system and aid in the targeted delivery of growth factors and genetic materials. Additionally, advanced biomaterials (hydrogels, bioresorbable polymers) serve as drug delivery vehicle for the regeneration of the tissues while acting as structural scaffold to create a regenerative microenvironment. New technologies (3D cell printing, micro-fluidic systems) provide excellent ability to precisely control the spatial deployment of therapeutic agents thereby enhancing local tissue regeneration and angiogenesis. While many of these modalities have demonstrated success in preclinical studies, there are still many challenges constraining the large-scale manufacture, standardization and regulatory approval for translation into the clinic. Therefore, there is a critical need for multidisciplinary collaborative efforts to further develop scalable and effective personalized regenerative therapies to treat patients with regenerative medicine. This review proposes a hierarchical framework integrating nano-scale carriers, biomaterial platforms, and therapeutic applications, offering a unified perspective that bridges material innovation with clinical translation in regenerative medicine.